StockData
Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc. (INO) stock

INONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$1.63+0.23 (+16.43%)

Close on Nov 17, 2026Market cap $168.54MP/E –Yield –

Inovio Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Inovio Pharmaceuticals's cash was $36.70M at Jun 30, 2026. For fiscal 2025 it was $58.50M, down 37.8% from the year before. Over ten years it grew -9.7% a year on average. The highest annual figure on record is $411.60M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$58.50M-37.8%
FY2024Dec 31, 2024$94.10M-35.2%
FY2023Dec 31, 2023$145.30M-42.6%
FY2022Dec 31, 2022$253.00M-37.0%
FY2021Dec 31, 2021$401.30M-2.5%
FY2020Dec 31, 2020$411.60M+359.9%
FY2019Dec 31, 2019$89.50M+10.2%
FY2018Dec 31, 2018$81.20M-36.3%
FY2017Dec 31, 2017$127.43M+21.6%
FY2016Dec 31, 2016$104.77M-35.7%
FY2015Dec 31, 2015$162.99M+74.1%
FY2014Dec 31, 2014$93.62M+77.9%
FY2013Dec 31, 2013$52.63M+284.7%
FY2012Dec 31, 2012$13.68M-54.7%
FY2011Dec 31, 2011$30.21M+38.3%
FY2010Dec 31, 2010$21.84M-27.9%
FY2009Dec 31, 2009$30.30M+114.6%
FY2008Dec 31, 2008$14.12M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$36.70M-22.7%
Q1 FY2026Mar 31, 2026$37.70M-44.9%
Q4 FY2025Dec 31, 2025$58.50M-37.8%
Q3 FY2025Sep 30, 2025$50.80M-40.1%
Q2 FY2025Jun 30, 2025$47.50M-57.0%
Q1 FY2025Mar 31, 2025$68.40M-35.2%
Q4 FY2024Dec 31, 2024$94.10M-35.2%
Q3 FY2024Sep 30, 2024$84.80M-49.4%
Q2 FY2024Jun 30, 2024$110.40M-43.4%
Q1 FY2024Mar 31, 2024$105.60M-52.8%
Q4 FY2023Dec 31, 2023$145.30M-42.6%
Q3 FY2023Sep 30, 2023$167.50M-40.6%
Q2 FY2023Jun 30, 2023$194.90M-44.0%
Q1 FY2023Mar 31, 2023$223.80M-37.9%
Q4 FY2022Dec 31, 2022$253.00M-37.0%
Q3 FY2022Sep 30, 2022$281.90M-28.6%
Q2 FY2022Jun 30, 2022$348.10M-21.5%
Q1 FY2022Mar 31, 2022$360.40M-30.5%
Q4 FY2021Dec 31, 2021$401.30M-2.5%
Q3 FY2021Sep 30, 2021$394.90M+17.1%
Q2 FY2021Jun 30, 2021$443.70M+19.4%
Q1 FY2021Mar 31, 2021$518.60M+92.1%
Q4 FY2020Dec 31, 2020$411.60M+359.9%
Q3 FY2020Sep 30, 2020$337.20M+259.5%
Q2 FY2020Jun 30, 2020$371.70M+250.7%
Q1 FY2020Mar 31, 2020$270.00M+110.9%
Q4 FY2019Dec 31, 2019$89.50M+10.2%
Q3 FY2019Sep 30, 2019$93.80M+9.7%
Q2 FY2019Jun 30, 2019$106.00M+10.9%
Q1 FY2019Mar 31, 2019$128.00M+13.5%
Q4 FY2018Dec 31, 2018$81.20M-36.3%
Q3 FY2018Sep 30, 2018$85.50M-39.7%
Q2 FY2018Jun 30, 2018$95.60M+3.9%
Q1 FY2018Mar 31, 2018$112.77M+25.8%
Q4 FY2017Dec 31, 2017$127.43M+21.6%
Q3 FY2017Sep 30, 2017$141.89M+18.6%
Q2 FY2017Jun 30, 2017$92.00M–
Q1 FY2017Mar 31, 2017$89.66M–
Q4 FY2016Dec 31, 2016$104.77M–
Q3 FY2016Sep 30, 2016$119.69M–

More Inovio Pharmaceuticals figures

See a number that looks wrong?